<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">By March 28, hydroxychloroquine received conditional approval via the FDA’s Emergency Use Pathway for treatment of COVID-19 infections, and just 3 weeks later, the FDA approved a phase III clinical trial of hydroxychloroquine for COVID-19 treatment, sponsored by Novartis.</p>
